Recent Updates
Recently added Catalysts

Minocycline

Phase 2

Major Depressive Disorder | Small molecule | Psychiatry |Pulmonx Corporation|Last Updated: Oct 19, 2020

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment168

FDA Designations

No designations recorded

Clinical trial landscape

Minocycline · 1 trial · 1 indication

Phase 2 1
NCT02456948Adjunct Minocyline in Treatment-resistant DepressionMajor Depressive Disorder
COMPLETED168 Analytics
PHASE2COMPLETED
Adjunct Minocyline in Treatment-resistant Depression
Major Depressive Disorder
NCT02456948168
Unlock trial analytics

Study Endpoints

Primary Endpoints

Response as per MADRS (Montgomery-Åsberg Depression Rating Scale)
6 weeks

Secondary Endpoints

Remission as per MADRS (Montgomery-Åsberg Depression Rating Scale)
6 weeks
HAM-D-17-Scale (17-item Hamilton Depression Rating Scale)
6 weeks
BDI-Scale (Beck Depression Inventory, Self Rating Scale)
6 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
MinocyclineEXPERIMENTALMinocycline and standard antidepressant treatment
PlaceboPLACEBO_COMPARATORPlacebo and standard antidepressant treatment

Interventions

NameTypeDescription
MinocyclineDRUG6 weeks 200mg/day Minocycline add-on
PlaceboDRUG6 weeks Placebo add-on
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: * Informed consent * male or female * between age 18 and 75 * BMI between 18 and 40 inclusive * Non-lactating, non-pregnant females of child-bearing potential must be willing to use an effective contraceptive method * All participants must fulfil diagnostic criteria of moderate ...

Countries:Germany
Unlock Eligibility Criteria

Competitive Landscape -Major Depressive Disorder 83 trials

Top 20 of 29 competitors

CompanyTickerTrialsLead PhaseDrugs
Neurocrine Biosciences, Inc.NBIX5PHASE3NBI-1065845
COMPASS Pathways Plc Sponsored ADRCMPS4PHASE3Psilocybin
AbbVie, Inc.ABBV2PHASE3Cariprazine
Johnson & JohnsonJNJ2PHASE3Esketamine, Midazolam
Axsome Therapeutics, Inc.AXSM2PHASE3Solriamfetol
Xenon Pharmaceuticals Inc.XENE3PHASE3Azetukalner
Definium Therapeutics, Inc.DFTX2PHASE3DT120
Eli Lilly and CompanyLLY1PHASE3Brenipatide
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK1PHASE3Vortioxetine
Cybin, Inc.HELP3PHASE3CYB003
Vanda Pharmaceuticals Inc.VNDA1PHASE3Milsaperidone
Neumora Therapeutics, Inc.NMRA1PHASE3NMRA-335140
AtaiBeckley Inc.ATAI3PHASE2VLS-01-203 BU
Alto Neuroscience, Inc.ANRO1PHASE2ALTO-300
ACADIA Pharmaceuticals Inc.ACAD1PHASE2ACP-211
Supernus Pharmaceuticals, Inc.SUPN1PHASE2SPN-821
Seaport Therapeutics, Inc.SPTX2PHASE2SPT-300
Sunshine Biopharma IncorporatedSBFM1PHASE2Mitizodone
Masimo CorporationMASI1PHASE1Diprivan, Astra-Zeneca
Abbott LaboratoriesABT1N/AUndisclosed
Unlock Competitive Intelligence